Finally, BMS-986205, an oral IDO1 inhibitor that has demonstrated encouraging activity in combination with nivolumab in advanced urothelial cancer [157], is being assessed in an ongoing phase II window of opportunity trial in patients with stage II-IV HNSCC in combination with nivolumab (NCT03854032). Here, IDO1 is linked to head and neck squamous cell carcinoma.